Axon Enterprise (AXON) and Seer, Inc. (SEER) represent contrasting ends of the equity landscape, each drawing interest from investors pursuing distinct growth stories. Axon has established itself as a profitable force in law-enforcement and public-safety technology, whereas Seer is still an early-stage player developing proteomics tools on the path to profitability. Placing them side by side highlights two separate risk-and-reward dynamics: one centered on a premium growth compounder and the other on a speculative small-cap backed by substantial cash and an unfolding commercial narrative. Growth-oriented investors, momentum participants, and those comparing performance across market caps may find this analysis relevant right now.
Axon Enterprise (AXON) leads globally in public-safety technology, linking TASER devices, body-worn and in-car cameras, drones and counter-drone systems, digital evidence management, and AI-powered software. Recent quarters have shown revenue expansion above 30% year over year, with annual recurring revenue reaching approximately $1.6 billion, net revenue retention close to 126%, and future contracted bookings surpassing $15 billion. Management has increased its full-year 2026 revenue guidance, pointing to strength in software, international markets, and enterprise segments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Even with this progress, the stock has underperformed lately. Shares have hovered near the $420–$425 range, down roughly 25% year-to-date and about 43% over the trailing year, following the launch of its Axon Body 5 camera at a major law-enforcement event in late October. Investors seem to be balancing a premium valuation—long supported by high-margin software and AI adoption—against pressures from tariffs, memory costs, and a shifting hardware mix. Analyst views stay largely positive, with a consensus Buy rating and an average price target above current levels, as the market absorbs execution details versus expectations.
Seer, Inc. (SEER) focuses on life sciences through its Proteograph platform, enabling deep, unbiased proteomics for biomarker discovery and large-scale studies with academic, biobank, and biopharmaceutical clients. Recent updates feature a collaboration profiling 10,000 samples in a Singapore population study, a doubling of independent peer-reviewed publications, and a positive patent ruling that strengthens its intellectual-property stance.
Financially, Seer stays small and unprofitable. First-quarter 2026 revenue fell 34% year over year to roughly $2.8 million amid weak academic funding and competition, alongside a net loss of about $16.8 million. The company reaffirmed its full-year 2026 revenue guidance of $16–18 million. Its balance sheet offers support, with approximately $220 million in cash and investments at the end of the first quarter—exceeding its market capitalization and providing a multi-year runway. Shares have traded near $1.90 recently, within a 52-week range of about $1.55 to $2.41, carrying event-driven risks from a rejected take-private offer and an ongoing shareholder contest.
The core difference lies in business model and maturity. Axon (AXON) produces hundreds of millions in quarterly revenue with expanding recurring software revenue and positive adjusted EBITDA, while Seer (SEER) is still establishing commercial traction with quarterly revenue in the low single-digit millions and persistent losses. Axon funds its growth through operations and a substantial backlog, whereas Seer relies on its cash reserves and share-buyback approach.
Risks diverge as well. For Axon, these include government budget cycles, valuation sensitivity, and margin impacts from hardware mix and component costs. For Seer, they revolve around cash burn, reliance on a soft academic funding environment, competitive pressures, and governance questions from an activist campaign. Sector exposure widens the gap: Axon ties to public-safety and defense spending, while Seer operates in life sciences and diagnostics. Axon provides scale and consistency at a demanding valuation, whereas Seer offers optionality and asset-backed support but limited near-term revenue clarity.
Considering factors such as trend consistency, relative stability, and underlying catalysts, Tickeron's AI would likely lean toward AXON over SEER currently. Axon's above-30% revenue growth, high net revenue retention, large contracted backlog, and generally favorable analyst consensus point to a more resilient trend, even amid valuation compression. Seer holds a stronger cash position relative to its market value yet shows less consistent momentum, negative free cash flow, and event-driven uncertainty. This view remains probabilistic: Axon's scale and steadiness currently outweigh Seer's speculative potential, though Seer's catalysts could shift the balance if commercial progress accelerates.
In my own research process, I have found Tickeron's AI Trading Bots helpful for evaluating automated approaches on names like these. The platform hosts hundreds of bots with varying styles, timeframes, and performance histories, allowing users to compare how different strategies align with current market conditions and specific tickers. This can provide a structured way to explore relative positioning without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company
Industry AerospaceDefense